Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
$92.23
$0.91(2.52%)
At close: 4:00 PM EST
$92.23
$0.91(2.52%)
Day’s Range― - ―
52-Week Range$34.88 - $120.74
Previous CloseN/A
Volume639.07K
Average Volume (3M)1.96M
Market Cap
$12.10B
Enterprise Value$13.43B
Total Cash (Recent Filing)$1.20B
Total Debt (Recent Filing)$1.68B
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Apr 30, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding131,170,440
10 Day Avg. Volume2,049,104
30 Day Avg. Volume1,960,172
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue13.68
Enterprise Value/Gross Profit21.22
Enterprise Value/Ebitda-35.92
Forecast
1Y Price Target
$132.58Price Target Upside43.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-2.63
Revenue Forecast (FY)$1.25B
Bulls Say, Bears Say
Bulls Say
Regulatory And ReimbursementFDA approval combined with a special Medicare reimbursement designation for a liquid biopsy could increase Medicare payment rates, broaden coverage, simplify ordering and expand testing volumes.
Screening Market ExpansionExpansion of the Shield blood screening product, including multi-cancer detection and partnerships with major lab providers, could broaden screening adoption and reach previously unscreened patients.
Therapy Selection And Minimal Residual Disease AdoptionGrowing adoption of therapy selection tests and minimal residual disease testing, supported by Medicare coverage for certain indications, could drive steady oncology revenue growth and capitalize on increased use of comprehensive genomic profiling.
Bears Say
Cash Burn And Profitability RiskContinued operating losses and persistent negative free cash flow create a material risk to achieving sustained profitability unless execution significantly reduces cash burn.
Legal And Patent RiskOngoing patent litigation, including a jury finding of infringement on a separate asserted patent and unresolved reexamination, could lead to enhanced damages or royalty obligations until fully resolved.
Revenue Quality And VisibilityRevenue beats influenced by accounting adjustments, coupled with an absence of forward guidance, raise questions about the underlying recurring demand and near-term revenue visibility.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $34.88 and its highest was $120.74 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $12.10B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Apr 30, 2026 which is in 58 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Feb 19, 2026. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.767 by -$0.233.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.81.
How many shares outstanding does Guardant Health have?
Guardant Health has 131,170,440 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$1 in its last earnings report, missing expectations of -$0.767. Following the earnings report the stock price went down -3.083%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$132.58 (43.75% Upside)
$132.58 (43.75% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 227.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $45.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.54%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Company Deck
GH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive growth and execution story: strong revenue and volume growth across oncology and screening, improved gross margins and reduced per-test costs (notably for Reveal), meaningful commercial traction for Shield (high adherence, ADLT reimbursement, EMR integrations, Quest/PathGroup partnerships), and improved profitability trends with a solid cash runway. At the same time, significant near-term investments—primarily in Shield—continue to drive company-wide cash burn and operating expenses, and several important upside catalysts (FDA approvals, additional reimbursements, co-promotion benefits) remain uncertain and are not included in the base guidance. Overall the company is growing rapidly with improving margins and clearer path to profitability, but execution and reimbursement risks and continued screening-related cash burn temper the near-term financial picture.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$132.58
▲(43.75% Upside)
Technical Analysis
Ownership Overview
3.43% Insiders
32.05% Mutual Funds
16.14% Other Institutional Investors
32.39% Public Companies and Individual Investors